Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca, Entain, Lloyds and more: What brokers said today
10:31am, Monday, 25'th Sep 2023Morgan Stanley sees biopharma sector as a 'safe haven'
10:01am, Monday, 25'th Sep 2023
Morgan Stanley (NYSE:MS) expects the EU biopharma sector to offer a safe haven from weakening growth/higher real yields. “Whilst we continue to favour growth/innovation narratives in biopharma over
AstraZeneca upgraded on potential for non-oncology assets
09:58am, Monday, 25'th Sep 2023
AstraZeneca PLC (LSE:AZN)'s assets beyond oncology offer significant upside potential, in the view of investment bank, Jefferies. The broker upgraded the pharmaceuticals giant to 'buy' from 'hold' and
Stocks making the biggest moves in premarket trading: AstraZeneca, Paramount, Nike and more
08:19am, Monday, 25'th Sep 2023
These are the stocks posting the largest moves in early trading.
3 Magnificent Growth Stocks to Buy Right Now
06:50am, Sunday, 24'th Sep 2023
Some might overlook AstraZeneca, but the stock has strong growth prospects. Eli Lilly continues to fire on all cylinders, with especially big opportunities for Mounjaro.
AstraZeneca ADSs Rise After Reporting Positive Results in Breast Cancer Drug Trial
12:10pm, Friday, 22'nd Sep 2023
AstraZeneca (AZN) ADSs rose after reporting its experimental breast cancer treatment made with Japanese partner Daiichi Sankyo showed positive high-level results in a Phase 3 trial.
AstraZeneca breast cancer drug gives drugs giant £5bn boost
07:33am, Friday, 22'nd Sep 2023
AstraZeneca PLC (LSE:AZN)'s share price surged by 2.6%, adding nearly £5 billion to the company's market value, following the announcement of encouraging results from an ongoing clinical trial on dat
AstraZeneca signals strong results from breast cancer drug trial
02:54am, Friday, 22'nd Sep 2023
AstraZeneca PLC (LSE:AZN) has hailed strong results from an ongoing trial on the effects of drug datopotamab deruxtecan in breast cancer patients. According to the pharmaceutical giant, the drug showe
AstraZeneca and Daiichi's breast cancer drug meets goal in study
02:52am, Friday, 22'nd Sep 2023
AstraZeneca said on Friday a drug it is developing with Daiichi Sankyo's to treat patients with a type of breast cancer met one of the main goals in a late-stage study.
AstraZeneca rises on completion of Pfizer gene therapy deal
04:31am, Wednesday, 20'th Sep 2023
AstraZeneca PLC (LSE:AZN) shares rose 2.4% to 10,868p after its Alexion rare disease unit sealed a deal to buy a portfolio of Pfizer's early-stage drugs to boost its footprint in the burgeoning fi
CHMP Endorses AstraZeneca's (AZN) Enhertu in Lung Cancer
12:47pm, Monday, 18'th Sep 2023
Data from a mid-stage study shows that treatment with AstraZeneca's (AZN) Enhertu achieved strong and durable tumor responses in certain non-small cell lung cancer patients.
AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths
01:02pm, Friday, 15'th Sep 2023
Currently, the S&P 500 and many sectors are outperforming the healthcare sector, presenting an opportunity to explore assets within this sector during the current period of apathy towards it. AstraZen
Investors Heavily Search AstraZeneca PLC (AZN): Here is What You Need to Know
10:31am, Friday, 15'th Sep 2023
Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
EU recommends approval of AstraZeneca and Daiichi's drug for a type of lung cancer
10:17am, Friday, 15'th Sep 2023
AstraZeneca said on Friday the European Medicines Agency's human medicines committee recommended its and Daiichi Sankyo's Enhertu drug as a monotherapy to treat patient with a type of non-small cell l
AstraZeneca succession sickness demands urgent fix
04:58am, Friday, 15'th Sep 2023
Can a CEO be worth $9 billion? That's the question posed by the 4% fall in AstraZeneca's shares following an article stating boss Pascal Soriot may soon resign.
